Relugolix placebo

DRUG7 trials

Conditions

Endometriosis Related PainHeavy Menstrual BleedingUterine FibroidUterine Fibroids

Phase 3

A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids

CompletedNCT02655237

TakedaUterine Fibroids

Start: 2016-03-05End: 2017-09-25Updated: 2019-03-22

A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids

CompletedNCT02655224

TakedaUterine Fibroids

Start: 2016-03-26End: 2017-05-19Updated: 2019-03-22

LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

CompletedNCT03049735

Myovant Sciences GmbHHeavy Menstrual Bleeding, Uterine Fibroid

Start: 2017-04-26End: 2020-08-24Updated: 2022-04-19

LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

CompletedNCT03103087

Myovant Sciences GmbHHeavy Menstrual Bleeding, Uterine Fibroid

Start: 2017-06-14End: 2020-09-16Updated: 2022-04-20

SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

CompletedNCT03204318

Myovant Sciences GmbHEndometriosis Related Pain

Start: 2017-12-07End: 2021-04-08Updated: 2021-06-28

SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

CompletedNCT03204331

Myovant Sciences GmbHEndometriosis Related Pain

Start: 2017-11-01End: 2021-05-31Updated: 2021-06-28

Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

RecruitingNCT06671548

Qilu Pharmaceutical Co., Ltd.Heavy Menstrual Bleeding, Uterine Fibroids

Start: 2024-01-15End: 2027-01-07Target: 120Updated: 2026-02-02

Fertility and Sterility2025-05-022 citations

A plain language summary describing changes in pain associated with uterine fibroids among women receiving relugolix combination therapy

Pain Management2024-09-01

P-308 Relugolix combination therapy vs relugolix monotherapy with transition to relugolix combination therapy for the treatment of endometriosis-associated pain: implications for cumulative benefit/risk profile

Human Reproduction2024-07-01

Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study

Human Reproduction2024-01-1834 citations

A Plain Language Summary to Learn About Relugolix Combination Therapy for the Treatment of Pain Associated with Endometriosis

Pain Management2023-11-013 citations

Relugolix combination therapy in Black/African American women with symptomatic uterine fibroids: LIBERTY Long-Term Extension study.

2023-10-187 citations

A plain language summary of the long-term relugolix combination therapy study for uterine fibroids

Journal of Comparative Effectiveness Research2023-07-21

Endometriosis Symptoms and Their Impacts on the Daily Lives of US Women: Results from an Interview Study.

2023-06-0110 citations

O-032 Effect of relugolix combination therapy in women with endometriosis-associated pain who received prior first-line hormonal treatment: SPIRIT 1 and 2

Human Reproduction2023-06-01

O-191 Effects of relugolix combination therapy (Relugolix-CT) on uterine fibroid (UF) and uterine volume through 52 weeks: post hoc analysis of the LIBERTY Long-Term Extension study

Human Reproduction2023-06-01

A Plain Language Summary of the Safety of Relugolix Combination Therapy and Improvement in Symptoms in Women with Uterine Fibroids from the LIBERTY 1 and LIBERTY 2 Studies

Pain Management2023-04-011 citations

Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas

Obstetrics and Gynecology2022-11-0237 citations

Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).

2022-06-0195 citations

Relugolix Combination Therapy for Uterine Leiomyoma–Associated Pain in the LIBERTY Randomized Trials

Obstetrics and Gynecology2022-05-0221 citations

The Burden of Uterine Fibroids from the Perspective of US Women Participating in Open-Ended Interviews.

2022-03-048 citations

Relugolix for oral treatment of uterine leiomyomas: a dose-finding, randomized, controlled trial

BMC Women s Health2021-10-2829 citations

O-131 The effect of time since surgical diagnosis of endometriosis on treatment outcomes with relugolix combination therapy in women with endometriosis-associated pain: SPIRIT program

Human Reproduction2021-07-01

Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results

BMC Women s Health2021-06-2127 citations

Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy

New England Journal of Medicine2021-02-17182 citations

Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women.

2019-10-0652 citations

1 more papers not shown

Relugolix placebo

Sponsors

Conditions

Phase 3

Related Papers